Lexicon Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US5288721047
Biotechnology & Medical Research
| Market Cap | 853M 735M 677M 634M 1.19B 81.11B 1.2B 8.01B 3.11B 39.44B 3.2B 3.13B 136B | P/E Ratio 2026 * |
-12.2x | P/E Ratio 2027 * | -10.1x |
|---|---|---|---|---|---|
| Enterprise Value | 853M 735M 677M 634M 1.19B 81.11B 1.2B 8.01B 3.11B 39.44B 3.2B 3.13B 136B | EV / Sales 2026 * |
22.3x | EV / Sales 2027 * | 42.3x |
| Free-Float |
98.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Lexicon Pharmaceuticals, Inc.
| 1 day | +7.56% |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Exton
CEO | Chief Executive Officer | 56 | 2024-07-07 |
Scott Coiante
DFI | Director of Finance/CFO | 59 | 2025-01-01 |
Michael Davies
CTO | Chief Tech/Sci/R&D Officer | - | 2025-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Samuel Barker
CHM | Chairman | 83 | 2004-12-31 |
Ray Debbane
CHM | Chairman | 71 | 2012-02-26 |
| Director/Board Member | 67 | 2007-08-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.56% | +0.99% | - | - | 853M | |
| +1.03% | +2.30% | +55.91% | +114.22% | 56.42B | |
| +2.72% | +3.26% | +46.05% | +44.91% | 44.54B | |
| +1.12% | +2.79% | -15.04% | -21.68% | 22.9B | |
| +1.17% | +3.85% | -0.89% | +403.86% | 21.21B | |
| +3.81% | -5.07% | +11.00% | -30.62% | 16.4B | |
| +0.15% | +2.24% | +9.32% | -39.30% | 15.4B | |
| -0.69% | +0.82% | +27.75% | +176.72% | 13.35B | |
| +5.27% | +5.54% | +19.65% | - | 12.36B | |
| +1.61% | +1.28% | +95.75% | +205.26% | 11.15B | |
| Average | +2.37% | +2.09% | +27.72% | +106.67% | 23.75B | |
| Weighted average by Cap. | +1.75% | +2.37% | +32.04% | +99.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.17M 32.87M 30.28M 28.37M 53.26M 3.63B 53.91M 359M 139M 1.76B 143M 140M 6.1B | 20.15M 17.36M 15.99M 14.98M 28.13M 1.92B 28.47M 189M 73.6M 932M 75.63M 74.02M 3.22B |
| Net income | -66.94M -57.65M -53.11M -49.75M -93.42M -6.37B -94.54M -629M -244M -3.1B -251M -246M -10.7B | -88.26M -76.02M -70.03M -65.6M -123M -8.39B -125M -829M -322M -4.08B -331M -324M -14.11B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
